Straits Times Index
3,269.27 -32.69 (-0.99%) Nikkei
28,546.98 +727.65 (+2.62%) Hang Seng
20,175.62 +93.19 (+0.46%) FTSE 100
7,500.89 +34.98 (+0.47%) BTC-USD
24,467.86 +513.71 (+2.14%) CMC Crypto 200
574.64 +3.36 (+0.59%)
AstraZeneca PLC (AZN.L)
| Previous close | 10,506.00 |
| Open | 10,568.00 |
| Bid | 10,702.00 x 0 |
| Ask | 10,704.00 x 0 |
| Day's range | 10,512.00 - 10,740.00 |
| 52-week range | 8,029.00 - 11,289.62 |
| Volume | |
| Avg. volume | 2,432,656 |
| Market cap | 171.668B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -58.80 |
| Earnings date | 29 Jul 2022 |
| Forward dividend & yield | 2.22 (2.05%) |
| Ex-dividend date | 11 Aug 2022 |
| 1y target est | 114.71 |
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
WILMINGTON, Del., August 12, 2022--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by a Food and Drug Administration (FDA)-approved test, and who have received a prior systemic therapy.
- Reuters
Chasing green goals, corporations push car fleet managers toward EVs
Large corporations are jumping on the "green" bandwagon left and right, which in turn is pushing firms that lease and manage car fleets to convert to electric vehicles (EVs) faster than they had ever thought possible. In late 2020, fleet management company ALD set a to have 30% of its new cars electrified by 2025 - a goal that seemed like a stretch because as recently as 2019 only one in 200 of ALD's new vehicles was an EV or a hybrid. But corporate clients chasing environmental, social and governance (ESG) goals pushed the leasing giant, a unit of Societe Generale, past that target in 2021.
- Zacks
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
